Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 4/2020

Open Access 01-04-2020 | Melanoma | Original Article – Clinical Oncology

Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument

Authors: Theresa Steeb, Kinan M. Hayani, Paul Förster, Raffael Liegl, Frédéric Toussaint, Max Schlaak, Carola Berking, Markus V. Heppt

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2020

Login to get access

Abstract

Purpose

Clinical practice guidelines provide recommendations for the management of diseases. In orphan conditions such as uveal melanoma (UM), guideline developers are challenged to provide practical and useful guidance even in the absence of high-quality evidence. Here, we assessed the methodological quality and identified deficiencies of international guidelines on UM as a base for future guideline development.

Methods

A systematic search was carried out in guideline databases, Medline and Embase until 27th May 2019 for guidelines on UM published between 2004 and 2019. Five independent reviewers assessed the methodological quality of the identified guidelines using the instruments “Appraisal of Guidelines for Research and Evaluation II” (AGREE II) and AGREE-REX (Recommendation EXcellence). Descriptive analysis was performed and subgroup differences were explored with the Kruskal–Wallis (H) test. The relationship between the individual domains and items of the instruments were examined using Spearman’s correlation.

Results

Five guidelines published from 2014 to 2018 by consortia of the United States of America, Canada and the United Kingdom (UK) were included. The highest scores were obtained by the UK guideline fulfilling 48–86% of criteria in AGREE II and 30–60% for AGREE-REX. All guidelines showed deficiencies in the domains “editorial independence”, “applicability”, and “recommendation”. Subgroup differences were identified only for the domain “editorial independence”.

Conclusion

The UK guideline achieved the highest scores with both instruments and may serve as a basis for future guideline development in UM. The domains “editorial independence”, “recommendation”, and “applicability” were identified as methodological weaknesses and require particular attention and improvement in future guidelines.
Appendix
Available only for authorised users
Literature
go back to reference Bedikian AY (2006) Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 46:151–166CrossRefPubMed Bedikian AY (2006) Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 46:151–166CrossRefPubMed
go back to reference Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed
go back to reference Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT, American Brachytherapy S (2003) The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 56:544–555CrossRefPubMed Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT, American Brachytherapy S (2003) The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 56:544–555CrossRefPubMed
go back to reference National Comprehensive Cancer Network (NCCN) (2018) Clinical Practice Guidelines in Oncology Uveal Melanoma, Version I. 2018 National Comprehensive Cancer Network (NCCN) (2018) Clinical Practice Guidelines in Oncology Uveal Melanoma, Version I. 2018
Metadata
Title
Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument
Authors
Theresa Steeb
Kinan M. Hayani
Paul Förster
Raffael Liegl
Frédéric Toussaint
Max Schlaak
Carola Berking
Markus V. Heppt
Publication date
01-04-2020
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 4/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-020-03141-w

Other articles of this Issue 4/2020

Journal of Cancer Research and Clinical Oncology 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.